Clinical Efficacy Of Recombinant Human Erythropoietin In Sepsis With Anemia

ObjectiveTo observe Clinical efficacy of recombinant human erythropoietin(rHuEPO) in sepsis with anemia.MethodsFrom June 2005to December2OOS,sixtysepsis with anemia patients in the Second Affiliated Hospital of Tianjin Medical University were divided into control group(n=30) and therapy with recombinant human erythroietin(rHuEPO) group(n=30). Compared with conventional therapy in control group,study drug(rHuEPO 6000 units ) was administered by subcutaneous injection at 48 hours after admission to the intensive care unit and continued every other day for two weeks in therapy group. Patients who received red blood cell(RBC) transfusion when their hemoglobin was lower than 80g/L.The data was expressed as(x±s),and were analyzed using Student's t test and Fisher' s exact test with SPSSll.5.A P value less than 0.05 indicated statistical significance.ResultsThe baseline hemoglobin was similar in two groups(P＞0.05).The hemoglobin for patients who received rHuEPO (105.87±11.48) g/L was higher than that in control group (91.23±19.89) g/L(P＜0.01).The units of RBC transfusions was lower in patients receiving rHuEPO(2.0±0.47) u compared with control group(2.63±0.43) u(P＜0.01).Mortality was not significantly different in two groups(P＞0.05).ConclusionsIn sepsis with anemia patients,administration of rHuEPO every other day results in a significant reduction in RBC transfusion,and these patients treated with rHuEPO achieve a higher hemoglobin level.